A 60-year-old with T2D, eGFR 45, UACR 400 mg/g on maximally tolerated ACE inhibitor. Next disease-modifying agent to reduce CKD progression and CV eve...

Question

A 60-year-old with T2D, eGFR 45, UACR 400 mg/g on maximally tolerated ACE inhibitor. Next disease-modifying agent to reduce CKD progression and CV events?

Accepted Answer

SGLT2 inhibitor

Answer

DPP-4 inhibitor

Answer

Thiazolidinedione

Answer

Basal insulin

Answer

Sulfonylurea

us-abfm MCQ (SBA): Diabetic Kidney Disease

A 60-year-old with T2D, eGFR 45, UACR 400 mg/g on maximally tolerated ACE inhibitor. Next disease-modifying agent to reduce CKD progression and CV events?